Market Overview

Oppenheimer Initiates Prothena With Outperform

Don't Let Offerings Blindside Your Thesis
10 Biggest Mid-Day Market Gainers

Analysts at Oppenheimer initiated coverage on shares of Prothena (NASDAQ: PRTA) with a Outperform rating.

The target price for Prothena is set to $40.

Prothena shares have dropped 1.50% over the past 52 weeks, while the S&P 500 index has surged 16.93% in the same period.

Prothena's shares fell 0.71% to close at $20.94 yesterday.

Latest Ratings for PRTA

Apr 2017Cantor FitzgeraldInitiates Coverage OnOverweight
Apr 2017PiperJaffrayInitiates Coverage OnOverweight
Mar 2017NomuraInitiates Coverage OnBuy

View More Analyst Ratings for PRTA
View the Latest Analyst Ratings

Posted-In: OppenheimerInitiation Analyst Ratings


Related Articles (PRTA)

View Comments and Join the Discussion!